CTOs on the Move

Coherus Biosciences

www.coherus.com

 
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team`s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million
  • www.coherus.com
  • 333 Twin Dolphin Drive Suite 600
    Redwood City, CA USA 94065
  • Phone: 800.794.5434

Executives

Name Title Contact Details

Funding

Coherus Biosciences raised $75M on 01/08/2019
Coherus Biosciences raised $50M on 02/02/2021

Similar Companies

Mixture Sciences Inc

Mixture Sciences Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetica Bio

Synthetica Bio is a privately held healthcare technology company based in Laguna Beach, California that is developing the next generation of safe and secure generative artificial intelligence (GenAI) solutions for the biopharma industry. The Synthetica Bio platform leverages and optimizes multiple large language models (LLMs) and vector databases to ingest real-time data streams and make actionable knowledge directly available to biopharma discovery, clinical, and commercial teams. The platform enables healthcare professionals to rapidly leverage the power of GenAI within compliance of data security standards required by the industry.

MicroGEM

At MicroGEM, we are transforming the landscape of DNA and RNA extraction. Come see how our single-tube extraction workflows can work for you!

Atara Biotherapeutics

Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients` lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Lynxcom Partners

Lynxcom Partners LLC is a Del Mar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.